2015
Ovarian cancer survival by tumor dominance, a surrogate for site of origin
Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes & Control 2015, 26: 601-608. PMID: 25771796, PMCID: PMC4561551, DOI: 10.1007/s10552-015-0547-y.Peer-Reviewed Original ResearchConceptsDominant tumorHazard ratioFallopian tubeEstrogen hormone replacement therapyConclusionThese preliminary findingsHormone replacement therapyDistal fallopian tubeRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsProportional hazards modelSite of originTubal originWorse survivalReplacement therapyOvarian tumorsCancer survivalOvarian cancerPathology reportsOnly subtypeBRCA1/2 mutationsHazards modelObjectivesRecent studiesTumorsPrognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards model
2014
Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer
Kotsopoulos J, Prescott J, De Vivo I, Fan I, Mclaughlin J, Rosen B, Risch H, Sun P, Narod SA. Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 2603-2606. PMID: 25159293, PMCID: PMC4221534, DOI: 10.1158/1055-9965.epi-14-0885.Peer-Reviewed Original ResearchConceptsLength z-scoreOvarian cancerZ-scoreTelomere lengthOvarian cancer-specific mortalityLarge population-based studyCancer-specific mortalityIncident ovarian cancerPopulation-based studyConfidence intervalsProportional hazards modelComputerized record linkagePeripheral blood leukocytesRelative telomere lengthNonserous tumorsChart reviewPrognostic roleVital statusPrognostic significanceLowest quartileBlood leukocytesHazards modelCancerCancer developmentQuartile
2012
Height, weight, BMI and ovarian cancer survival
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA. Height, weight, BMI and ovarian cancer survival. Gynecologic Oncology 2012, 127: 83-87. PMID: 22713293, DOI: 10.1016/j.ygyno.2012.05.038.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer survivalOvarian cancer-specific mortalityCancer-specific mortalityHazard ratioCancer survivalOvarian cancerLarge population-based studyBMI 5 yearsFatal gynecologic malignancyPopulation-based studyEpithelial ovarian cancerConfidence intervalsOvarian cancer prognosisProportional hazards modelChart reviewGynecologic malignanciesClinicopathologic featuresHistologic subtypeMass indexVital statusModifiable factorsRisk factorsHazards modelCancer prognosis